Logo

AVIR

Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc. • NASDAQ
$3.10 ▲ 1.64% (+0.05)
Market Cap $242.20 M
52w High $4.02
52w Low $2.46
Dividend Yield 0%
P/E -1.75
Volume 146.21K
Outstanding Shares 78.13M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $45.567M ▲ $-42.049M ▼ 0% $-0.53 ▼ $-41.749M ▼
Q2-2025 $0 $38.926M ▲ $-37.161M ▼ 0% $-0.44 ▼ $-41.319M ▼
Q1-2025 $0 $35.601M ▼ $-34.272M ▼ 0% $-0.4 $-38.937M ▼
Q4-2024 $0 $38.922M ▲ $-33.543M ▼ 0% $-0.4 ▼ $-33.214M ▼
Q3-2024 $0 $17.279M $-31.151M 0% $-0.37 $-30.862M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $329.309M ▼ $342.963M ▼ $27.183M ▼ $315.78M ▼
Q2-2025 $379.713M ▼ $391.605M ▼ $27.189M ▼ $364.416M ▼
Q1-2025 $425.436M ▼ $439.964M ▼ $28.88M ▲ $411.084M ▼
Q4-2024 $454.721M ▼ $464.668M ▼ $25.801M ▼ $438.867M ▼
Q3-2024 $482.813M $490.957M $32.436M $458.521M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-42.049M ▼ $-40.375M ▼ $41.303M ▲ $-11.305M ▲ $-10.377M ▲ $-40.375M ▼
Q2-2025 $-37.161M ▼ $-32.87M ▼ $15.29M ▼ $-14.093M ▼ $-31.673M ▼ $-32.87M ▼
Q1-2025 $-34.272M ▼ $-30.563M ▼ $85.608M ▲ $-347K ▼ $54.698M ▲ $-30.563M ▼
Q4-2024 $-33.543M ▼ $-30.397M ▼ $-3.37M ▲ $0 ▼ $-33.767M ▲ $-30.397M ▼
Q3-2024 $-31.151M $-23.035M $-122.013M $117K $-144.931M $-23.035M

Five-Year Company Overview

Income Statement

Income Statement Atea looks like a classic clinical‑stage biotech on the income side: almost no recurring revenue and steady losses as it funds drug development. The company had a brief period of meaningful revenue and profit a few years ago, likely from a one‑off partnership or licensing deal. Since then, reported revenue has essentially disappeared, and results have moved back to consistent annual losses. Expenses appear relatively controlled and have not exploded over time, but they still clearly outweigh any income. That means the business is still firmly in the investment phase, with the story driven by pipeline progress rather than current earnings power.

Balance Sheet

Balance Sheet The balance sheet is a relative bright spot. Atea holds a solid cash position compared with its size and has no debt, which gives it flexibility and reduces financial risk. Total assets have been gradually drifting lower as cash is spent to fund research and trials. Shareholders’ equity remains positive but is also trending down as losses accumulate. In simple terms, the company is spending its cash cushion to push its programs forward, but it still has a meaningful buffer left. The lack of borrowings and the still‑healthy equity base are important strengths, especially for a company that does not yet generate steady revenue.

Cash Flow

Cash Flow Cash flow reflects the same pattern: money going out to fund development, not coming in from products. Operating cash flow has been consistently negative in recent years, showing ongoing cash burn from day‑to‑day operations and R&D. Capital spending is minimal, so free cash flow is largely the same as operating cash flow. The pace of cash use appears manageable relative to the cash reserves and the stated runway into the second half of the decade. Still, if clinical timelines slip or costs rise, the company could eventually need fresh funding, either from partners, capital markets, or both.

Competitive Edge

Competitive Edge Atea is a small player in a big, competitive antiviral space, but it has carved out a focused niche. Its strength lies in a specialized technology platform for oral antivirals that target a core enzyme used by many RNA viruses. This gives it potential breadth across multiple diseases and can make it harder for viruses to develop resistance. The lead program in Hepatitis C aims to improve on existing treatments with shorter therapy, strong efficacy even when patients miss doses, and a clean safety and drug‑interaction profile. If late‑stage data confirm this, the product could be competitive in a mature but still significant market. On the other hand, Atea competes against much larger companies with established HCV brands, sales forces, and deep pockets. It is also heavily dependent on just a few programs, which concentrates risk. The company’s decision to seek a partner for HCV underscores both the opportunity and the need for external commercial muscle.

Innovation and R&D

Innovation and R&D Innovation is the core of Atea’s value proposition. Its proprietary nucleotide prodrug platform is designed to create potent, convenient oral antivirals with a high barrier to resistance. The lead Hepatitis C combination has several differentiators: a dual mechanism of attacking the virus, activity against resistant strains, and the potential for shorter and more forgiving treatment. Early‑stage results support this profile, but the true test will be the ongoing Phase 3 trials. Beyond HCV, Atea is extending the same technology into areas with fewer or no approved treatments, such as Hepatitis E, and has previously explored dengue and RSV. This shows the platform is adaptable and not tied to a single virus. The flip side is that R&D is expensive, and the company has already taken cost‑saving steps, including staff reductions. Balancing financial discipline with sustained innovation will be an ongoing challenge.

Summary

Atea is a pre‑revenue, clinical‑stage biotech with a focused antiviral platform, a potentially best‑in‑class Hepatitis C regimen in late‑stage trials, and a growing early pipeline in other viral diseases. Financially, it combines persistent losses and ongoing cash burn with a relatively strong cash cushion and no debt. The business is not yet built for current profits; it is built around the prospect that one or more drug candidates eventually succeed and reach the market. The main opportunities lie in confirming the strength of the HCV program in Phase 3, securing a strong commercial or development partner, and expanding the platform into under‑served diseases like Hepatitis E. The main risks are concentrated: heavy dependence on a single lead program, clinical and regulatory uncertainty, competition from established antiviral players, and the possibility of needing more capital if timelines or costs shift. Overall, Atea’s story is about scientific potential and execution over the next few years, rather than about near‑term earnings or dividends. Outcomes will depend heavily on trial results and partnership decisions expected around the middle to late part of this decade.

NEWS

November 19, 2025 · 7:00 AM UTC

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

Read more

November 12, 2025 · 4:05 PM UTC

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 7, 2025 · 8:00 AM UTC

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Read more

November 5, 2025 · 7:00 AM UTC

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

Read more

October 22, 2025 · 7:00 AM UTC

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

Read more